Health In Tech, Inc. (HIT) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals: strong early 2025 revenue momentum and disciplined capital management were positives, but declining margins, increased expenses, and lack of shareholder returns were concerns. The Q&A highlighted management's cautious approach to guidance, which could dampen investor enthusiasm. Overall, the financial results and cautious outlook suggest a neutral stock price reaction in the near term.
Key Financial Performance
Cash and Cash Equivalents $7.8 million, up from $2.4 million (more than 3x increase) due to strong liquidity position following the IPO and disciplined capital management.
Total Liabilities $2.6 million, down from $5.4 million (reduction) reflecting improved financial position.
Total Revenue Q4 2024 $4.9 million, down from $5.2 million (small decline) primarily due to a decrease in underwriting modeling revenue from $2 million to $1.7 million due to increased offering of A-rated insurance policies.
Gross Margin Q4 2024 77.4%, down from 81.8% (decline) driven by increased cost of revenue due to new distribution channel partner fees and captive management fees.
Total Operating Expenses Q4 2024 $4.1 million, up from $2.8 million (increase of $1.3 million) mainly due to a reversal of compensation accrual in 2023.
Income from Continuing Operations Q4 2024 Loss of $0.1 million, compared to a profit of $1 million in Q4 2023 (decline) reflecting the overall revenue changes.
Adjusted EBITDA Q4 2024 $0.5 million, down from $1 million in Q4 2023 (decrease) due to revenue changes.
Total Revenue Full Year 2024 $19.5 million, up 1.8% year-over-year (modest growth) due to a strategic approach to moderate growth and focus on higher program fees.
Revenue from Fees Full Year 2024 $12.8 million, up 17.5% year-over-year (growth) due to higher program fees for better network access.
Underwriting Model Revenue Full Year 2024 $6.6 million, down from previous year (decline) reflecting a shift in focus.
Gross Margin Full Year 2024 79.2%, down from 88% in 2023 (decline) due to increased cost of revenue.
Total Operating Expenses Full Year 2024 $14.4 million, up $0.9 million from 2023 (increase) due to personnel expansion.
Research and Development Expenses Full Year 2024 $2.8 million, up $0.8 million from 2023 (increase) driven by expansion in IT compliance and new product development.
Income from Continuing Operations Full Year 2024 $0.7 million, down from $2.5 million in 2023 (decline) reflecting overall revenue changes.
Adjusted EBITDA Full Year 2024 $2.3 million, down from $4.8 million in 2023 (decrease) due to revenue changes.
Unaudited Revenue January and February 2025 $5.7 million, exceeding total Q1 2024 revenue (over 50% year-over-year growth) indicating strong early momentum.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Products: Introduced new Spec & agg products, a stop-loss healthcare plan designed to simplify the claims process for TPAs and carriers.
Technology Innovations: Launched a transformative technology initiative aimed at delivering unique solutions for large-group underwriting.
eDIYBS Platform Enhancements: Advancing underwriting capabilities in the eDIYBS platform to serve mid-sized businesses with over 150 employees.
Market Expansion: Expanding focus beyond small businesses (5-150 employees) to include mid-sized businesses (over 150 employees), unlocking a significant expansion in total addressable market.
Market Opportunity: The small business self-funded medical insurance market projected to grow from $186 billion in 2023 to $242 billion by 2028.
Operational Efficiencies: Streamlined workflows and eliminated inefficiencies through technology-driven solutions, enabling faster proposal generation in about two minutes.
Workforce Adjustments: Reduced headcount from 91 to 80 to strengthen organizational structure after rapid growth.
Strategic Shifts: Moderated growth in 2024 to strengthen organizational structure and focus on foundational initiatives.
Leadership Expansion: Expanded executive leadership team with experienced professionals to drive market expansion and operational efficiencies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Fluctuations: Tim Johnson acknowledged that market fluctuations can be challenging, indicating potential risks related to external economic factors affecting the company's performance.
Regulatory Compliance: The company is focused on strengthening its internal controls and compliance framework, highlighting the importance of adhering to regulatory requirements as a risk management strategy.
Supply Chain Challenges: The discussion on the increased costs associated with new distribution channel partner fees and captive management fees suggests potential supply chain challenges impacting operational costs.
Competitive Pressures: The company faces competitive pressures in the healthcare and insurance industry, particularly as it aims to innovate and provide cost-effective solutions in a market that has seen little innovation.
Stock Price Volatility: Tim Johnson addressed concerns regarding the recent sharp decline in stock price, attributing it to external market forces and indicating the risk of stock volatility affecting investor confidence.
Operational Scaling: The company moderated its growth to strengthen organizational structure, indicating risks associated with scaling operations and ensuring that processes keep pace with growth.
Revenue Dependency: The decline in underwriting modeling revenue due to a shift towards A-rated insurance policies indicates a risk related to revenue dependency on specific product offerings.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: Health In Tech has made critical investments in IT infrastructure, functionality enhancements, and cybersecurity to support scalable expansion. They introduced new Spec & agg products and launched a technology initiative for large-group underwriting.
Market Opportunity: The U.S. healthcare and insurance industry is a $6-trillion market with significant potential for disruption, particularly in the small business self-funded medical insurance market, projected to grow from $186 billion in 2023 to $242 billion by 2028.
Leadership Expansion: The company expanded its executive leadership team to drive growth, including promotions and new hires in key operational and strategic roles.
Revenue Expectations: Health In Tech anticipates further investment in automation and expansion into new markets, with unaudited revenue for January and February 2025 reaching approximately $5.7 million, exceeding the total revenue for Q1 2024.
Financial Position: The company enters 2025 with $7 million in cash, a strong liquidity position, and no debt, indicating a solid foundation for future growth.
Growth Strategy: The company aims to drive revenue growth and maintain profitability through innovative products and services, focusing on underserved small and medium-sized businesses.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Health In Tech, Inc. has not announced any specific share buyback program or dividend program during the earnings call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you just help us understand what happened with the change in the underwriting model?
A:Our underwriting model, DIYBS, needed more features based on client feedback. Our new CTO is improving the tool for faster and more efficient changes.
Q:What do you mean by the strength of Vitable's Direct Primary Care model?
A:Vitable's model allows for a fixed fee for services, providing predictable income for doctors and is a growing industry.
Q:Does the January 1 contract signing affect you, and what happened there?
A:Yes, we saw strong momentum with $5.7 million revenue in January and February, a 50% year-over-year increase.
Q:Can we think of the $5.7 million as a run rate?
A:It's just one month of accrual accounting, and we can't project yet, but we are seeing strong growth compared to last year.
Q:How are you using AI for underwriting?
A:We use AI tools to gather and organize medical data quickly, which helps in risk-scoring and speeds up the underwriting process.
Q:Is it reasonable to think that most of the opportunity for mid-sized customers came on January 1?
A:1/1 is the biggest month for larger groups, but there are opportunities throughout the year for mid-sized companies.
Q:What factored into the decline in the number of lives?
A:We took a strategic pause to moderate growth and strengthen infrastructure, which affected the number of lives.
Q:How do you think about your initiatives for spending on software development in 2025?
A:We have a six-month lead time for new products, and we expect to see results from 2024 investments in 2025.
Q:How do you plan to expand your customer reach?
A:We plan to use a mix of brokers and our unique tools to grow customer reach.
Q:Review of Unclear Management Responses
A:Management did not provide a clear projection on the $5.7 million revenue run rate, stating they cannot give guidance at this time.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Allen Klee
Director Allen
ET Transcript
Group Conference
Inc Chief
Klee Maxim
Ms today
Oxley Hi
section hello
sector requirement
website end
HIT Transcript
Health In Tech, Inc. (HIT) Q3 2025 Earnings Call Transcript
Positive11-11
The earnings call reflects strong financial health with improved operating expenses and positive cash flow. Strategic partnerships and product innovations are expected to drive growth. Despite some uncertainties in the large employer market, the company's initiatives like the 3-year rate hold and blockchain development are promising. The Q&A session revealed positive analyst sentiment, although some details were withheld. Overall, the positive financial performance and strategic growth plans suggest a positive stock price movement in the near term.
Health In Tech, Inc. (HIT) Q2 2025 Earnings Call Transcript
Positive7-23
The earnings call summary indicates strong financial performance with positive cash flow, effective cost management, and strategic partnerships driving growth. The Q&A reveals management's proactive approach in leveraging partnerships and technology for market expansion, despite some vague responses about new products. The company's solid financial health and growth strategy, coupled with a significant market opportunity, suggest a positive stock price movement. However, the lack of specific guidance on new products and potential expansion limits the sentiment from being 'strong positive.'
Health In Tech, Inc. (HIT) Q1 2025 Earnings Call Transcript
Positive4-16
The earnings call highlights strong financial performance with 56% revenue growth, improved operating leverage, and a solid cash position. The company's strategic focus on AI-backed underwriting and channel distribution supports future growth. Despite competitive pressures and economic risks, management's confidence in maintaining gross margins and operating leverage is positive. The lack of a share repurchase program is a neutral factor. Overall, the positive financial metrics, strategic initiatives, and optimistic guidance suggest a positive stock price movement in the next two weeks.
Health In Tech, Inc. (HIT) Q4 2024 Earnings Call Transcript
Unknown3-21
The earnings call presented mixed signals: strong early 2025 revenue momentum and disciplined capital management were positives, but declining margins, increased expenses, and lack of shareholder returns were concerns. The Q&A highlighted management's cautious approach to guidance, which could dampen investor enthusiasm. Overall, the financial results and cautious outlook suggest a neutral stock price reaction in the near term.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
